What caused the 829.33% increase in institutional long shares MRQ despite BTAI's 77.30% share price decline by August 2025?

The significant increase in institutional long shares for BioXcel Therapeutics, Inc. (BTAI) during a period of reported share price decline presents an interesting divergence in market sentiment. While the question highlights a 77.30% share price decline by August 2025, Fintel data indicates that BTAI's share price as of August 6, 2025, was $3.31, representing a 244.79% increase over the prior year. This suggests that any substantial decline may have occurred prior to the last 12 months leading up to August 2025, or the stated percentage refers to a different timeframe or metric. Nevertheless, institutional accumulation during periods of volatility or perceived undervaluation is a common strategy.

Several factors could be driving this institutional accumulation:

• Anticipated Clinical Milestones: BioXcel Therapeutics has been actively progressing its lead neuroscience asset, BXCL501 (IGALMI®). In August 2025, the company expected topline data from its SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia. An FDA meeting was also scheduled in August 2025 to support a potential sNDA submission for label expansion of IGALMI® in the at-home setting. Earlier in May 2025, the company announced enrollment completion for this pivotal trial.
• Expanded Market Opportunity: BioXcel Therapeutics has identified a significantly larger total addressable market (TAM) for BXCL501 in the at-home setting than previously estimated. Market research suggests approximately three agitation episodes per month in the home setting, compared to a prior estimate of 1.2 episodes based on historical claims data, indicating a substantial unmet medical need and commercial opportunity.
• Analyst Confidence: Despite past price movements, analysts maintain a positive outlook. As of August 5, 2025, the average one-year price target for BTAI was $16.83, with a high forecast of $69.30, significantly above the August 2025 share price. This strong analyst sentiment could be influencing institutional investors who see substantial upside potential.
• Long-Term Value Proposition: Institutional investors may be taking a long-term view, accumulating shares based on the potential of BTAI's pipeline and the future commercial success of IGALMI® in its expanded indications, rather than focusing on short-term price fluctuations.

This pattern suggests that institutions might be positioning themselves ahead of anticipated positive news flow and market expansion for BTAI's key drug candidates.